Summit Therapeutics Inc. (NASDAQ:SMMT) Q2 2024 Results Conference Call August 6, 2024 9:00 AM ET

Company Participants

Dave Gancarz - Chief Business and Strategy Officer
Bob Duggan - Chairman and Chief Executive Officer
Maky Zanganeh - Chief Executive Officer, President
Manmeet Soni - Chief Operating Officer
Allen Yang - Chief Medical Officer

Conference Call Participants

Dara Azar - Stifel
Yigal Nochomovitz - Citigroup
Mitchell Kapoor - H.C. Wainwright

Operator

Good morning, and welcome to Summit Therapeutics Second Quarter 2024 Earnings and Update Call. All participants will be listen-only mode until the question-and-answer portion of this call. [Operator Instructions] Please note that today's call is being recorded. [Operator Instructions] And at this time, I would like to turn the call over to Dave Gancarz, Summit Therapeutics' Chief Business and Strategy Officer. You may proceed.

Dave Gancarz

Good morning, and thank you for joining us. Our press release was issued earlier this morning and is available on the homepage of our website. Our Form 10-Q was also filed earlier this morning and is available on our website. Today's call is being simultaneously webcast, and an archived replay will also be made available later today on our website, www.smmttx.com.

Joining me on the call today is Bob Duggan, our Chairman of the Board and Chief Executive Officer; Dr. Maky Zanganeh, our Chief Executive Officer and President; Manmeet Soni, our Chief Operating Officer and Chief Financial Officer; and Dr. Allen Yang, our Chief Medical Officer.

Before we get started with the rest of the call, I would like to note that some statements made by our management team and some responses to questions that we may make today may be considered forward-looking statements based on our current expectations. Summit cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Please refer to our SEC filings for information about these risks and uncertainties. Summit undertakes no obligation to update these forward-looking statements, except as required by law. Following comments from Bob, Maky, Manmeet, we will take questions.

With that, I would like to turn the call over to Bob.

Bob Duggan

Thank you, Dave. Good morning, everyone, and thank you for joining us today. We are very proud of the recent accomplishments of Team Summit and the expanding positive information that continues to be brought to light surrounding ivonescimab, our lead investigational asset. The past few months have been pivotal to the positive development and awareness of ivonescimab as well as in expanding physician, caretaker, hospital, payer and patient awareness of Summit Therapeutics' mission and vision, namely to build a viable organization that makes a significant positive difference for the betterment of patients encountering serious unmet oncology medical needs. Specifically, ivonescimab created positive Phase 3 data updates from HARMONi-A and HARMONi-2, both of which were randomized single region clinical trials in non-small cell lung cancer conducted by our partners at Akeso.